1 / 23

Study Design

Randomized phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas (TRS).

neva
Télécharger la présentation

Study Design

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Randomized phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas (TRS) Sant P. Chawla, Andrew Hendifar, Michael Leahy, Antoine Italiano, Shreyaskumar Patel, Peter Hohenberger, Armando Santoro, Arthur P. Staddon, Nicolas Penel, Sophie Piperno-Neumann, Pilar Lardelli, Antonio Nieto, Carmen Kahatt, Jean-Yves Blay

  2. Eligible patients MRCL (n= 40) Other TRS (n= 40) PS= 0 PS= 1-2 PS= 0 PS= 1-2 RANDOMIZATION (1:1) Study Design • An adaptive design in chemonaïvepatients with advanced TRS, stratified by performance status and subtype, then randomized to receive: • Trabectedin: 1.5 mg/m2 in 24h iv infusion q3wk • Doxorubicin based chemotherapy (DXCT): single agent 75 mg/m2 q3wk, or 60 mg/m2 combined with ifosfamide 6-9 g/m2 q3wk

  3. Study Objectives • Primary: Progression free survival (PFS) of trabectedinvs DXCT • Secondary: • PFS at 6 months • Response rate (RR) • Overall survival • Safety • PFS/RR analyzed by investigator assessment for all randomized patients • PFS/RR analyzed by independent review only for confirmed TRS patients

  4. Results: Baseline Characteristics Trabectedin (n=61) DXCT (n=60) Age (yr) Median (range) 47 (19-78) 49 (19-78) Sex Male / female 36 (59%) / 25 (41%) 38 (63%) / 22 (37%) ECOG PS 0 28 (46%) 29 (48%) 1 32 (52%) 30 (50%) 2 1 (2%) 1 (2%) Sarcoma type by Investigator MRCL 28 (46%) 28 (47%) Other 33 (54%) 32 (53%) Sarcoma type by central pathology MRCL 23 (38%) 17 (28%) Other 28 (46%) 20 (33%) Not confirmed* 10 (16%) 23 (38%) * Wrong diagnosis 4 (7%) and 9 (15%) patients of the trabectedin and DXCT arms, no evidence of translocation in 3 (5%) and 2 (3%) patients, and lack of available material for central review in 3 (5%) and 12 (20%) patients

  5. Histology According Central Diagnosis (TRS Confirmed Patients N=88)

  6. Results: Baseline Characteristics Trabectedin (n=61) DXCT (n=60) Disease Extension Locally advanced 18 (30%) 13 (22%) Metastatic 43 (70%) 47 (78%) 33 (54%) 38 (63%) Prior surgery (radical/palliative) 24 (39%) Prior radiotherapy 21 (35%) Number of sites involved at baseline, Median (range) 2 (1-5) 2 (1-8) Months from first diagnosis to randomization, Median (range) 10 (1-187) 8 (0-310)

  7. Patient Exposure

  8. Censoring • A high percentage of patients were censored in both arms • Main reasons for censoring: • Surgical removal of lesions • 24% in trabectedin arm and 16% in the DXCT arm • Administration of a new anticancer therapy (chemotherapy or radiotherapy) before progression of the disease • 18% in trabectedin arm and 24% in DXCT arm • Importantly, 35-40% patients in either arm ended up receiving the drug in the other arm • Patients in trabectedin arm also received DXCT • Patients in DXCT arm also received trabectedin

  9. Results: Response Rate

  10. Results: Response Rate

  11. Median: 16.1 months (95% CI, 5.5-21.9) Median: 8.8 months (95% CI, 5.5-12.7) Hazard ratio: 0.85, p=0.5551. Log rank p=0.5533 Results: PFS by Investigators

  12. Median:18.8 months (95% CI, 5.7-not reached) Median: 8.3 months (95% CI, 7.1-25.0) Hazard ratio: 0.86; p=0.6992. Stratified log-rank p=0.9573 Results: PFS by Independent Review

  13. Median: 38.9 months (95% CI, 24.2-nr) Median: 27.3 months (95% CI, 21.3-39.6) Hazard ratio: 0.77, p=0.3672. Log rank p=0.3659 Results: Overall Survival

  14. OS in MyxoidLiposarcoma Median: 95% CI (-) Median: 33.1 95% CI (21.2-39.6) Hazard ratio: 0.25, p=0.0453. Log rank p=0.0314

  15. Results: Hematologic and Other Laboratory Toxicity

  16. Results: Non-Hematologic Toxicity

  17. Summary • The study was underpowered to detect any statistical significant differences in the two arms due to high rate of censoring in both arms • Overall, no statistically significant differences in PFS/OS were observed • Median PFS was 19 mo. in trabectedin arm vs. 8 mo. in DXCT arm • Median OS was 39 mo. in trabectedin arm vs. 27 mo. in DXCT arm • Safety profiles for trabectedin and DXCT were consistent with previous studies • Ability to administer trabectedin over prolonged periods without cumulative toxicity may allow for longer disease control • Trabectedin should be further explored in a definitive randomized study in myxoidliposarcoma patients

  18. Back-up slides

  19. Censoring Reasons

  20. Subsequent Chemotherapy Agents in Censored Patients

  21. Responders’ Histology

  22. Discontinuations and Dose Reductions • Administrationdelays and dosereductionsoccurred more frequently in thetrabectedinarm, partiallyduetotheprolongedtreatmentduration. • Transaminaseincreasewasthemainreasonfordosereduction • Neutropenia wasthemostcommon cause of administrationdelay.

  23. Results: Safety in DXCT

More Related